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Introduction
Type 1 diabetes (T1D), one of  the most common chronic and autoimmune diseases in childhood, devel-
ops through the interaction of  an incompletely defined combination of  genetic susceptibilities (1–3) and 
environmental factors (4–6), which translate into immune destruction of  islet β cells and consequent 
hyperglycemia. Autoimmunity in T1D is often characterized by defect(s) in one or several immune 
regulatory mechanisms (7). A defect apparently linked to a single pathway may, in turn, represent the 
result of  multiple alterations in physiological mechanisms (8). The functional consequences of  genetic 
variability in the pathogenesis of  T1D — and whether those could be targeted pharmacologically — 
have been unclear (9).
A defect in indoleamine 2,3-dioxygenase 1 (IDO1), which is responsible for immunoregulatory 
tryptophan catabolism, impairs development of immune tolerance to autoantigens in NOD mice, 
a model for human autoimmune type 1 diabetes (T1D). Whether IDO1 function is also defective 
in T1D is still unknown. We investigated IDO1 function in sera and peripheral blood mononuclear 
cells (PBMCs) from children with T1D and matched controls. These children were further included 
in a discovery study to identify SNPs in IDO1 that might modify the risk of T1D. T1D in children 
was characterized by a remarkable defect in IDO1 function. A common haplotype, associated with 
dysfunctional IDO1, increased the risk of developing T1D in the discovery and also confirmation 
studies. In T1D patients sharing such a common IDO1 haplotype, incubation of PBMCs in vitro 
with tocilizumab (TCZ) — an IL-6 receptor blocker — would, however, rescue IDO1 activity. In an 
experimental setting with diabetic NOD mice, TCZ was found to restore normoglycemia via IDO1-
dependent mechanisms. Thus, functional SNPs of IDO1 are associated with defective tryptophan 
catabolism in human T1D, and maneuvers aimed at restoring IDO1 function would be therapeutically 
effective in at least a subgroup of T1D pediatric patients.
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Indoleamine 2,3-dioxygenase 1 (IDO1) — a powerful immunosuppressive enzyme catalyzing the 
first, rate-limiting step in l-tryptophan (Trp) catabolism — depletes Trp and produces immunoregula-
tory molecules collectively known as kynurenines (10–14). IDO1 functioning is, in turn, modulated at 
multiple levels (i.e., transcriptional and/or posttranslational levels; refs. 11, 12, 15). In fact, the expres-
sion of  IDO1 protein may not be sufficient per se for full enzymatic activity (16, 17) because IDO1 
proteasomal degradation occurs in a microenvironment dominated by IL-6 (18, 19). Moreover, genetic 
variants may likewise influence IDO1 expression and activity (20–23). Therefore, IDO1’s defective 
activity may be the result of  alteration(s) in one or multiple mechanisms modulating the enzyme, 
either positively or negatively.
In NOD mice, a prototypic model for T1D, IDO1 expression — and hence immune tolerance to islet 
autoantigens — is defective in DCs stimulated with IFN-γ, the main IDO1 inducer (24, 25), owing to a 
massive production of  IL-6 in pancreatic lymph nodes (PLNs) (26). Maneuvers capable of  correcting the 
IDO1 defect in NOD mice will, however, restore autoantigen-specific tolerogenesis by DCs in vivo (25, 27), 
prolong survival of  pancreatic islet grafts (28), and normalize glycemia in diabetic animals (29).
In humans, IDO1 expression and activity are known to exhibit relatively large interindividual vari-
ability, particularly under pathological conditions, often as a result of  SNPs in the enzyme gene (20–22). 
However, SNPs in IDO1 and any associated functional defects impacting on human T1D, currently with 
increasing prevalence in children (30), have not been formally proven (31).
Here, we investigated IDO1 expression and activity, as well as the association of  SNPs in IDO1 and 
T1D development in peripheral blood mononuclear cells (PBMCs) from pediatric patients with T1D 
(3–17 years of  age; 0.1- to 15-year disease duration), as compared with age-matched controls (i.e., not 
affected by metabolic or immune pathologies). Our data indicated that (i) pediatric T1D is associated 
with impaired IDO1 activity in PBMCs; (ii) IDO1 SNPs influences the risk of  developing T1D; (iii) 
defective IDO1 activity is associated with a specific IDO1 genotype at rs7820268 and increased expres-
sion of  the IL-6 receptor (IL-6R) in T1D patients; and (iv) an IL-6R blocker, currently in use for juvenile 
arthritis, restores IDO1 activity in vitro in PBMCs from a subgroup of  T1D patients with defective 
IDO1 and normalizes glycemia in the majority of  diabetic NOD mice in an IDO1-dependent fashion.
Results
Defective Trp catabolism in children with T1D. Significant changes in systemic Trp catabolism have been 
reported in several human diseases (32, 33). To ascertain whether dysfunctional Trp catabolism could be 
associated with T1D, sera from pediatric T1D patients and controls (Table 1) were analyzed for levels of  
Table 1. Characteristics of patients with T1D and control subjects recruited in the functional study
T1D patients Control subjects P
Number 165 87
Females/males 63/102 46/41
Mean age (years) 11.87 ± 0.25A 10.17 ± 0.38 0.0002B
BMI 19.61 ± 0.28C 19.99 ± 0.61D 0.5262
Mean age of onset (years) 6.98 ± 0.31 ND
Mean duration of T1D (years) 4.89 ± 0.26 ND
Mean HbA1c (%) 7.96 ± 0.10 ND
Glycemia (mg/dl) 198 ± 6.30C ND
Autoimmune comorbidities (%)
Celiac disease 21 (12.7)E 0
Autoimmune thyroiditis 12 (7.2) 0
Vitiligo 1 (0.6) 0
Juvenile arthritis 1 (0.6) 0
Overall 31 (18.7) 0
AData are shown as the mean (± SEM). All T1D patients were being treated with insulin, and some of them showed evidence of other diseases 
(i.e., comorbidities). BThe difference may be imputable to the fact that medical care for T1D — more than for other conditions — is provided to 16- 
to 17-year-olds in pediatric wards. CData available for 158 patients. DData available for 65 subjects. ENumber of patients with the specific disease 
(percentage over total number of patients). ND, not determinable.
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Trp and l-kynurenine (Kyn), the respective substrate and product of  the IDO1’s enzymic activity. Kyn 
concentrations in sera from T1D patients were significantly lower (P < 0.001) than those from controls, 
whereas Trp levels did not differ in the 2 groups (P = 0.2594) (Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.96244DS1). The Kyn/
Trp ratio, considered to be an indicator of  systemic IDO1 activity (20), was significantly lower (P < 
0.001) in sera from T1D patients relative to controls (Supplemental Figure 1A and Supplemental Text).
Although IDO1 is an enzyme recognized as an authentic immune regulator (11, 13, 15), other enzymes 
such as Trp 2,3-dioxygenase (TDO) and IDO2 catalyze the same reaction along the Kyn pathway (15, 34). 
In particular, liver TDO, which is responsible for the catabolism of >95% of Trp entered with the diet, may 
greatly contribute to circulating levels of Kyn (35). We thus examined whether the data obtained from sera were 
reflected in expression and activity changes of Trp catabolizing enzymes in PBMCs from T1D patients and 
control subjects that were either left untreated or stimulated with IFN-γ at 100 or 1,000 U/ml for 48 hours. We 
first evaluated the expression of IDO1, IDO2, and TDO2 (coding for TDO) in PBMCs, either unstimulated or 
stimulated with IFN-γ at 100 or 1,000 U/ml. By means of real-time PCR, IDO2 and TDO2 (coding for TDO) 
expressions were found to be negligible in both control and T1D PBMCs under all conditions (data not shown). 
In contrast, IDO1 expression was upregulated in PBMCs from both control and T1D subjects in response 
to IFN-γ, but no significant difference could be found in samples from T1D patients as compared with their 
counterparts (i.e., control PBMCs; Figure 1A). In contrast, IDO1 protein was expressed to a lower extent in 
response to 1,000 U/ml of IFN-γ in PBMCs from T1D patients as compared with controls (Figure 1, B and C).
Figure 1. Tryptophan catabolism is reduced in PBMCs of pediatric patients with T1D. (A) Real-time PCR analysis of IDO1 transcripts in PBMCs, either 
unstimulated (0) or stimulated for 48 hours with IFN-γ at 100 or 1,000 U/ml, normalized to the expression of ACTB (encoding β-actin), and presented 
relative to results in untreated cells (dotted line, 1-fold; n =33–16, Ctrl; n = 97–18, T1D). (B) Immunoblot analysis of IDO1 and β-tubulin in lysates of periph-
eral blood mononuclear cells (PBMCs), either unstimulated (0) or stimulated for 48 hours with IFN-γ at 100 or 1,000 U/ml, from 3 representative control 
subjects and T1D patients (indicated at the right side). (C) IDO1/β-tubulin ratios of scanning densitometry data obtained from immunoblot analyses as 
in B (all groups, n = 27). (D) Kyn levels in supernatants of PBMCs treated as in A from control subjects (n = 74, 67, and 38 for 0, 100, and 1,000 U/ml IFN-γ, 
respectively) or T1D patients (n = 169, 145, and 55 for 0, 100, and 1,000 U/ml IFN-γ, respectively). (E) Linear regression analysis of l-kynurenine (Kyn; 
μM) versus IDO1/β-tubulin in T1D PBMCs unstimulated or stimulated as in A (r2 = 0.7099 and P < 0.0001; n = 27). Ctrl, nondiabetic subjects. T1D, diabetic 
patients. Data (mean ± SEM) in A and C–E are the result of 3 independent measurements performed in triplicate. Data in A and C were analyzed by 2-way 
ANOVA followed by post hoc Bonferroni’s test. The Kruskal-Wallis with post hoc Dunn’s test was used for the analysis of E. **P < 0.01; ***P < 0.001.
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Figure 2. Defective tryptophan catabolism in T1D patients is associated with a specific IDO1 genotype. (A) Human IDO1 gene structure and SNP 
localization. The tag SNPs are identified in bold. Exons and untranslated regions are depicted in dark and light gray, respectively. Genotype frequen-
cies for the T1D patients and healthy controls were used to phase haplotype configuration. Rare haplotypes (frequency <2%) are not represented. 
(B) IDO1 mRNA (measured as in Figure 1A) in peripheral blood mononuclear cells (PBMCs) stratified according to rs7820268 genotypes (n = 8–36). (C) 
IDO1/β-tubulin protein ratios of scanning densitometry data obtained from immunoblot analyses as in Figure 1, B and C, from PBMCs stratified as 
in B (all groups, n = 5–11). (D) l-kynurenine (Kyn) production by PBMCs according to rs7820268 genotypes (n = 7–42). Ctrl, nondiabetic subjects. T1D, 
diabetic patients. Data (mean ± SEM) in panels B–D are the results of 3 independent measurements performed in triplicates. Data in panels B–D were 
analyzed by 2-way ANOVA, followed by post hoc Bonferroni’s test.*P < 0.05; **P < 0.01, ***P < 0.001.
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On evaluating IDO1 catalytic activity, no differences were found in Kyn productions by PBMCs from 
T1D patients as compared with control subjects under basal conditions (i.e., in the absence of  any inflam-
matory stimuli in vitro; Figure 1D). As expected, PBMCs from control subjects released significantly high-
er amounts of  Kyn in response to IFN-γ at the concentration of  100 U/ml and more so at 1,000 U/ml. In 
contrast, Kyn levels in supernatants of  PBMCs from T1D patients treated with IFN-γ at 100 U/ml were 
not significantly different from those in unstimulated T1D cells, but they were significantly lower than in 
control counterparts (P < 0.001). The highest concentration of  the cytokine — 1,000 U/ml — did increase 
Kyn production by T1D PBMCs, although to a lesser extent than in control PBMCs stimulated with the 
same amount of  IFN-γ (P < 0.001) (Figure 1D). Importantly, ratios of  IDO1 to β-tubulin protein expres-
sions would significantly and positively correlate with the concentrations of  Kyn released in culture super-
natants by PBMCs, unstimulated or stimulated with different concentrations of  IFN-γ, from both control 
subjects (data not shown) and T1D patients (Figure 1E). However, no significant relationship was found 
between Kyn values in sera and in vitro Kyn production by PBMCs, either unstimulated or stimulated with 
IFN-γ in both T1D patients and controls (Supplemental Figure 1). Multiple regression analysis was used 
to test if  participants’ characteristics (age, sex, BMI, disease duration, HbA1c, glycemia, and presence or 
absence of  comorbidities) would significantly predict the responsiveness of  PBMCs from T1D patients to 
IFN-γ in vitro in terms of  transcript and protein expressions or catalytic activity of  IDO1, but no effect of  
any of  those parameters was found (data not shown).
Thus, our data indicated the existence of  a significant defect of  Trp catabolism in sera as well as in 
PBMCs from pediatric T1D patients. Reduced Trp catabolism in PBMCs could be attributed to a defect 
intrinsically linked to protein but not transcript expressions of  IDO1 or other Trp catabolizing enzymes, 
or to any other tested patients’ variables, including percentages of  distinct DC subsets (data not shown). 
The capacity of  IFN-γ to upregulate IDO1 transcripts equally well in PBMCs from healthy controls 
and T1D patients also excluded any contribution of  IFN-γ unresponsiveness to the effect. Lack of  a 
significant correlation of  Kyn in sera versus PBMC supernatants indicated that (i) systemic Kyn may 
Table 2. Description of IDO1 SNPs evaluated in T1D patients and control subjects.
SNP rs number Chromosome 
position
Alleles Gene location HapMap MAF MAF in our study HWE
rs9657182 39908329 T→C Near gene 5′ 0.483 0.441 0.7199
rs3808606 39911856 C→T Near gene 5′ 0.481 0.477 0.6630
rs10089078 39912420 G→A Near gene 5′ 0.336 0.346 1.0000
rs7820268 39920010 C→T Intron 0.305 0.378 0.5727
rs3739319 39927802 G→A Intron 0.429 0.476 0.6273
Chromosome positions at 8p12–p11 are from NCBI database (www.ncbi.nlm.nih.gov), assembly GRCh 37. MAFs and HWE tests were calculated collectively 
for T1D patients and healthy controls. SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.
 
Table 3. Multivariate analysis of the association of genetic variants in IDO1 with the risk of T1D in the discovery and confirmation studies.
Genetic risk factors
Discovery study 
(n = 732)
Confirmation study (n = 412) Combined studies (n = 1,144)
Adjusted ORA 
(95% CI)
P value Adjusted OR  
(95% CI)
P value Adjusted OR  
(95% CI)
P value
SNP model
rs7820268, CC 
genotype
1.44 (1.05–1.98) 0.028 1.69 (1.13–2.54) 0.014 1.51 (1.18–1.93) 0.001
Haplotype model
H1/H1 haplotype 1.70 (1.03–2.80) 0.036 1.90 (1.03–3.51) 0.042 1.76 (1.20–2.58) 0.005
OR, odds ratio. AORs were adjusted for patient age and sex. Multivariate analyses were based on conditional logistic regression. In the SNP model, the CT 
+ TT genotype combinations at rs7820268 were the reference categories. Because the CC genotype at rs7820268 conferring risk for T1D was present in the 
H1/H1 diplotype, the H1/H2 + H2/H2 combinations were the reference categories in the haplotype model
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Figure 3. Peripheral blood mononuclear cells (PBMCs) from T1D patients express abnormal levels of SOCS3 and IL-6R. (A) Absolute expression levels 
of SOCS3, IL6, and IL6R transcripts in untreated PBMCs normalized to ACTB expression (n = 26–97). (B) Real-time PCR analysis of SOCS3, IL6, and IL6R 
transcripts in PBMCs treated as in Figure 1A. Data were normalized to expression of ACTB (encoding β-actin) and presented relative to results in untreated 
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not represent a reliable measure of  IDO1 activity in immune cells, in contrast to previous reports (20, 
21, 36), and/or (ii) an immune and metabolic disease such as T1D may be characterized by a significant 
defect in Trp catabolism involving liver TDO, as well, whose specific contribute cannot, however, be 
determined in live patients.
Association of  genetic variation in IDO1 with defective Trp catabolic activity in PBMCs. Considering that 
genomic heterogeneity (20–23) could have masked the presence of  a defect in IDO1 transcript expression in 
a subgroup of  patients (see also Supplemental Text), we examined the possibility of  an association between 
genetic variability in IDO1 and development of  T1D.
We compared the frequency of  5 haplotype-tagging SNPs (tagSNPs) in the IDO1 gene (capturing a 
total of  9 variants based on their ability to tag surrounding variants with an r2 > 0.9) (Figure 2A and Table 
2), using genomic DNA samples from both T1D patients (n = 265) and control subjects (n = 447). The 
rs7820268 SNP displayed a significantly different allele and genotype distribution among T1D patients and 
control subjects (P = 0.0083 and P = 0.0382, respectively; Supplemental Table 1 and 2). Of  note, an associa-
tion analysis test of  rs7820268 genotypes using a genetic dominant model (CC versus T carriers) confirmed 
a significant association of  the CC genotype with an increased risk of  T1D (P = 0.0259; data not shown). 
Haplotype association analysis further confirmed the role of  IDO1 SNPs in T1D (Supplemental Table 3). In 
particular, the H1 haplotype promoted a significantly higher risk of  T1D (P = 0.0021), and the haplotypes 
H4 and H5 conferred, instead, protection from T1D (P = 0.0053 and P = 2.188 × 10−6, respectively). In a 
multivariate model adjusted for age and sex, the odds ratio (OR) for the CC genotype at rs7820268 and the 
H1/H1 diplotype containing this genotype was 1.4 (P = 0.028) and 1.7 (P = 0.036), respectively (Table 3). 
The results of  both genotype and haplotype association tests were further validated in a confirmation case 
control study (OR, 1.69 [P = 0.014], and OR, 1.90 [P = 0.042], respectively) and by a meta-analysis includ-
ing all enrolled patients (OR, 1.51 [P = 0.001], and OR, 1.76 [P = 0.005]).
To determine whether IDO1 SNPs could have an impact in our experimental setting, we compared 
IDO1 expression and Kyn production among PBMCs, either unstimulated or stimulated with 100 U/ml 
IFN-γ (i.e., a concentration at which most T1D PBMCs will not respond; Figure 1D) from subgroups of  
control subjects and T1D patients stratified on the basis of  the rs7820268 genotype (Figure 2, B–D). We 
found no significant difference of  IDO1 transcripts among control or T1D groups, either unstimulated or 
stimulated with the cytokine and harboring distinct genotypes (Figure 2B). In contrast, when assessing 
T1D toward control samples with the same genotype, a significant reduction in IDO1 protein expression 
(Figure 2C) and Kyn levels (Figure 2D) was found to occur in association with the CC and CT but not 
TT genotype at rs7820268 in the presence of  IFN-γ. At variance with PBMCs, no significant impact of  
the rs7820268 SNP could be found on systemic Trp metabolism, further supporting the hypothesis that 
enzymes other than IDO1 may contribute to Kyn sera levels.
In order to gain insight into the functional meaning (currently unknown) of  rs7820268, a SNP resid-
ing in the IDO1’s intron between exons 4 and 5, we evaluated whether this could be associated with an 
alternative splicing of  IDO1 transcripts and, thus, loss of  function of  the IDO1 enzyme. By means of  the 
Human Splicing Finder bioinformatics tool (Universal Mutation Database) (37), the C allele was predicted 
to create a potential intronic splicing enhancer site. To directly investigate this possibility, IDO1 amplicons 
were obtained by using primers specific for exons 4 and 5, as well as cDNA from 8 and 6 PBMC samples 
from T1D patients and healthy subjects (covering all rs7820268 variations), respectively; were sequenced; 
and were compared with each other. No difference in sequence and length could be found for any ampli-
con, i.e., from either T1D or controls samples (data not shown). A microRNA has recently been found to 
interfere with the expression of  molecules involved in proteasomal degradation (38). Moreover, in NOD 
mice as well as in T1D patients, microRNAs downregulate the expression of  PD-L1, an immunoregulato-
ry molecule (39). We thus examined the possibility that the rs7820268 SNP could be associated with the 
production or loss of  microRNAs. However, careful analysis performed using the PolymiRTS database 
cells (dotted line, 1-fold; n = 23–98). (C) Linear regression analyses of SOCS3, IL6, and IL6R expression vs. disease duration in T1D PBMCs stimulated with 
IFN-γ at 1,000 U/ml (n = 22). (D) IL-6 protein levels measured by ELISA in culture supernatants of PBMCs from control or T1D subjects either untreated or 
stimulated with IFN-γ (1,000 U/ml) for 48 hours (n = 15–22). (E) Immunoblot analysis of IL-6R, SOCS3, and β-tubulin in lysates of PBMCs, either unstim-
ulated (0) or stimulated for 48 hours with IFN-γ at 1,000 U/ml, from 1 representative control subject and 1 T1D patient (indicated at the right side). (F) 
IL-6R/β-tubulin and SOCS3/β-tubulin ratios of scanning densitometry data obtained from immunoblot analyses as in E (all groups, n = 27). Ctrl, nondia-
betic subjects. T1D, diabetic patients. Data (mean ± SEM) are the results of 4 independent measurements performed in triplicates. Data in panels A, B, D, 
and F were analyzed by 2-way ANOVA, followed by post hoc Bonferroni’s test. *P < 0.05; **P < 0.01.
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version 3.0 (40) ruled out this possibility (data not shown). Based on the available data, the most probable 
hypothesis could be that the rs7820268 SNP is in linkage disequilibrium (LD) with biologically relevant 
variability in other genes coding for proteins involved in proteasomal degradation, many of  which reside 
on chromosome 8 (http://www.uniprot.org/docs/humchr08), the same of  IDO1.
Therefore, our analyses of  IDO1 SNPs demonstrated a significantly different distribution of  the 
rs7820268 SNP in 2 independent association studies, further supporting the importance of  IDO1 in 
autoimmune diabetes. Although the functional meaning of  the different rs7820268 genotype distribution 
between control subjects and T1D patients remains unclear, our data would confirm posttranscriptional 
Figure 4. Tocilizumab (TCZ) restores tryptophan catabolism in peripheral blood mononuclear cells (PBMCs) from a subgroup of T1D children. (A) l-kynurenine 
(Kyn) levels in supernatants of PBMCs, either unstimulated (medium) or stimulated for 48 hours with IFN-γ at 100 U/ml in the presence or absence of TCZ (10 
μM), from control subjects (n = 34) or T1D patients (n = 114). (B) Kyn production as in A from T1D PBMCs subdivided in responders (R; n = 39) vs. nonresponders 
(NR; n = 75) due to TCZ significant effects detectable in IFN-γ−stimulated cells at the individual level (analyzed in triplicate samples). (C) Kyn production as in 
B from NR T1D PBMCs further subdivided in IDO1+ (n = 43) vs. IDO1− (n = 32) due to the capacity of IFN-γ to significantly or not significantly upregulate the Kyn 
production at the individual level (as in B), respectively. (D) TGF-β production from T1D PBMCs, either untreated or treated as in A, and subdivided in TCZ R, NR 
IDO1+, and NR IDO1− groups. (E) IDO1 rs7820268 and (F) IL6R rs2228145 genotype distribution in R, NR IDO1+, and NR IDO1− T1D PBMCs. (G) Ratios of AC + CC (i.e., 
protective) and AA (nonprotective) IL6R rs2228145 genotype in R, NR IDO1+, and NR IDO1− T1D PBMCs. Ctrl, nondiabetic subjects. T1D, diabetic patients. Data 
(mean ± SEM; A–D) are the result of 4 independent measurements performed in triplicate. Kruskal-Wallis with post hoc Dunn’s test was used for the analysis of 
A. Data in panels B–D were analyzed by 2-way ANOVA, followed by post hoc Bonferroni’s test. *P < 0.05; **P < 0.01; ***P < 0.001.
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events as playing a major role in influencing variability of  blood IDO1 activity observable within a healthy 
population of  children, as well as between control and T1D subjects.
Occurrence of  abnormal expression of  IL-6R and SOCS3 in PBMCs from T1D patients. In mouse DCs (18), proin-
flammatory IL-6 drives regulatory proteolysis of IDO1 via upregulation of SOCS3, a small molecule capable 
of directly binding the Trp catabolizing enzyme, thus promoting its ubiquitination and subsequent proteasomal 
degradation (14, 15, 18). Conflicting data on IL-6 serum levels in autoimmune forms of diabetes have been 
reported. Although some groups reported lower levels of serum IL-6 in children with T1D, others found nor-
mal, if  not increased, levels of IL-6 (41, 42). Interestingly, Hundhausen et al. observed a significant increase 
in surface protein expression of IL-6R but not of SOCS3 transcripts in effector T cells purified from PBMCs 
of adult patients with T1D versus matched controls (42). Analysis of IL6, IL6R, SOCS3, and IDO1 expression 
in PBMCs from healthy versus T1D children — as conducted with public microarray data obtained by others 
(43) — demonstrated the existence of significantly higher transcript levels of SOCS3 and more so of IL6R but 
not IL6 and IDO1 in samples from T1D patients at disease onset (Supplemental Figure 2).
We measured IL-6 serum levels in our cohorts of  T1D patients versus controls, but no significant vari-
ation was found (data not shown). On evaluating transcript expression of  IL-6, IL-6R, and SOCS3 genes in 
PBMCs from our cohort of  children with T1D versus matched controls, no significant difference could be 
found for IL6 expression in cells either untreated (Figure 3A) or stimulated with IFN-γ (Figure 3B). In con-
trast, IL6R and more so SOCS3 expressions were higher in T1D as compared with control PBMCs under 
IFN-γ stimulation (Figure 3B) but not basal (Figure 3A) conditions. A linear regression analysis indicated 
that the in vitro treatment of  PBMCs from patients with T1D with 1,000 U/ml IFN-γ increased SOCS3 but 
decreased IL6 and IL6R expressions over disease duration (Figure 3C).
We next investigated whether the differences observed in the expression of  IL6R and SOCS3 transcripts 
could translate into significant protein variations. IL-6 levels were measured in supernatants from T1D or 
control PBMCs, cultured with or without IFN-γ, but no significant difference was found on contrasting 
treatment groups (Figure 3D). In contrast, IL-6R and SOCS3 proteins were expressed to a significantly 
higher extent in response to 1,000 U/ml of  IFN-γ but not under basal conditions in PBMCs from T1D 
patients as compared with controls (Figure 3, E and F).
Thus, our data suggested that pediatric T1D is accompanied by a deregulated IL-6R−SOCS3 axis, an 
alteration traceable to aberrant IL-6R expression rather than IL-6 production that becomes evident under 
inflammatory conditions.
Restoration of  Trp catabolism by tocilizumab in PBMCs from T1D patients. Tocilizumab (TCZ; Actemra, 
RoActemra) is a humanized mAb specific for human IL-6R that is currently approved for adult rheu-
matoid arthritis and systemic juvenile idiopathic arthritis in both Europe and the US. Interestingly, the 
effects of  TCZ immunotherapy are currently being studied in T1D patients in the ongoing EXTEND 
clinical trial (https://clinicaltrials.gov/ct2/show/NCT02293837). We thus explored whether IL-6R 
blockade could restore Trp catabolism in PBMCs from T1D patients. To this purpose, we measured 
IDO1 activity in PBMCs from T1D patients and control subjects cultured with medium or IFN-γ at 100 
U/ml, in the presence or absence of  TCZ (10 μM). In vitro incubation with TCZ did not increase IDO1 
activity significantly in PBMCs from control subjects under any conditions (Figure 4A). In contrast, 
TCZ made IFN-γ capable of  upregulating Kyn release to a significant, though moderate, extent in T1D 
Table 4. Comparative profile of IDO1 expression (IDO1 mRNA and IDO1 protein) and activity (Kyn), IL-6R protein expression, and TGF-β 
production in subgroups of T1D PBMCs either untreated or incubated with TCZ.
TCZ R NR IDO1+ NR IDO1–
IDO1 mRNA – ++ ++ ±
IDO1 protein – – ++ –
IL-6R protein – ++ + ++
Kyn – – ++ –
Kyn + ++ + –
TGF-β – + ++ +
TGF-β + ++ ++ +
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PBMCs as compared with the same cells incubated with medium or TCZ alone. No TCZ effect could be 
observed in T1D PBMCs not stimulated with the cytokine.
To evaluate whether a variability in TCZ responsiveness could have masked the effect in PBMCs of  indi-
vidual patients, we searched for the presence of  effective TCZ responders (i.e., PBMCs in which the drug did 
significantly increase Kyn production in at least 2 experiments; hereafter referred to as R) and nonresponders 
(NR) in the tested T1D population. The subgroup of  TCZ NR (65.8% of  the whole population) was capable 
Figure 5. Tocilizumab (TCZ) restores normoglycemia in diabetic NOD mice via an IDO1-dependent mechanism. NOD mice proficient (A–D) or deficient 
(E–H) in Ido1 expression were treated i.p. with saline (control) or TCZ at the dose of 5 mg/kg every other day for 3 weeks and once a week for the next 3 
weeks. (A and E) Percentages of diabetic animals (i.e., treated with TCZ or saline when showing a glycemia of 200–250 mg/dl) whose course of glycemia 
at the individual level is represented over time in B and F (n = 8 per group; 1 experiment representative of 3). (C and G) Histology of 1 representative mouse 
per group. Scale bars: 50 μM. (D and H) Degree of insulitis in the various groups. Data of diabetes incidence (A and E) were analyzed by Kaplan-Meier and 
survival curves were compared by log-rank test. ***P < 0.001.
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of  significantly upregulating Trp catabolism in response to IFN-γ (but not to IFN-γ plus TCZ). In contrast, 
TCZ R PBMCs (34.2%) increased their Kyn production exclusively in the copresence of  IFN-γ and TCZ 
(Figure 4B). Moreover, incubation with TCZ and IFN-γ rendered cells from the TCZ R group capable of  
producing Kyn to an extent comparable with healthy subjects (i.e., approximately 1 μM; Figure 4, A and B).
A further analysis of  the TCZ NR population led to the identification of  2 distinct TCZ NR subpopula-
tions (Figure 4C), in which TCZ either did not exert any modulatory effect on Kyn production (NR IDO1−) 
or significantly impaired Kyn release as induced by IFN-γ alone (NR IDO1+). To investigate other possible 
functional effects of  TCZ on PBMCs that might corroborate the differences in the 3 T1D subgroups, we 
measured the levels of  TGF-β — an immunosuppressive cytokine that promotes IDO1 upregulation and 
acts as a functional antagonist of  IL-6 on Trp catabolism (44–46) — in culture supernatants. Data showed 
that R and NR IDO1− samples released lower levels of  the cytokine as compared with the NR IDO1+ 
group, under both basal conditions and in the presence of  IFN-γ alone (Figure 4D). However, R — but not 
NR IDO1− or NR IDO1+ — cells produced significantly higher levels of  TGF-β in the presence of  TCZ, 
in an IFN-γ−independent fashion. Besides an overrepresentation of  the CT genotype in R samples, anal-
ysis of  the rs7820268 genotype in the 3 subgroups revealed a prevalence of  the TT (i.e., T1D protective; 
Supplemental Table 2 and 3) or CC (T1D pathogenetic) genotype in NR IDO1+ and NR IDO1− patients, 
respectively (Figure 4E). Interestingly, all comorbidities (i.e., 13 cases out of  overall 114 T1D patients) were 
found to segregate in the NR groups (4 in IDO1+ and 9 in IDO1−; data not shown).
Therefore, although the majority of  PBMCs from T1D patients may exhibit defective IDO1 activity 
(Figure 1) and a deregulated IL-6R−SOCS3 axis (Figure 3), together with a few alterations in the cytokine 
profile (Supplemental Figure 4 and Supplemental Text), the use of  an IL-6R blocker allowed us to identify 
3 subgroups of  patients characterized by distinct profiles of  Trp catabolism, TCZ responsiveness, and pro-
duction of  TGF-β, as well as distinct frequencies of  IDO1 rs7820268 genotypes.
Differential distribution of  a functional SNP of  the IL6R gene in the 3 T1D subgroups. Similarly to IDO1, 
the genes coding for IL-6 and IL-6R are also characterized by the presence of  SNPs. Several SNPs have 
been described in the IL6 gene, namely rs1800795, a promoter SNP thas is known to influence the expres-
sion of  the cytokine and has been correlated with many distinct inflammatory diseases, including type 2 
diabetes (47). Moreover, the rs2228145 AC and CC genotype variants of  IL6R have been shown to confer 
protection from several inflammatory diseases, including T1D (48). In fact, the AC and CC genotypes 
are functional — i.e., they determine a lower expression of  membrane IL-6R and, thus, a reduced IL-6R 
signaling activity as compared with the rs2228145 AA genotype.
In order to strengthen the link between IL-6R signaling and IDO1 in T1D and evaluate additional fea-
tures of  the 3 T1D subgroups, we performed a genetic polymorphism analysis of  IL6 rs1800795 and IL6R 
rs22281145 SNPs in parallel with measurements of  IL-6 and IL-6R transcript and protein expressions in 
PBMCs, either unstimulated or stimulated with IFN-γ, from the 3 T1D subgroups (TCZ R, NR IDO1+, 
and NR IDO1−). No differential IL-6 transcript and protein expressions, as well as no distinct distribution 
of  the IL6 rs1800795 SNP, could be observed in the 3 subgroups (data not shown). The analysis of  IL6R, 
along with that of  IDO1 transcript expressions (Supplemental Figure 3A), revealed that both the R and NR 
IDO1+ subgroups upregulated IDO1 expression in response to the cytokine to a similar extent, which was 
significantly greater than that found in NR IDO1− samples. In contrast, samples from R — but not NR 
IDO1+ — patients expressed higher levels of  IL6R transcripts in response to IFN-γ as compared with the 
other groups. Western blotting analyses indicated that, in the presence of  IFN-γ at 100 U/ml, IL-6R protein 
expression was significantly higher in R and NR IDO1− samples (Supplemental Figure 3, B and C). Howev-
er, as expected from the data of  IDO1 activity (Figure 4, B and C), no upregulation of  the IDO1 protein by 
IFN-γ alone could be observed in NR IDO1− and R cells, at variance with NR IDO1+ cells.
The genetic polymorphism analysis of  the IL6R rs22281145 SNP in our cohort of  patients revealed 
that the AA, AC, and CC genotypes were differentially distributed among the 3 subgroups of  T1D patients 
(TCZ R, NR-IDO1+, and NR-IDO1−) (Figure 4F). Moreover, the results showed that the ratio of  AC + 
CC/AA (i.e., protective/nonprotective genotype in T1D) was higher in T1D patients with no detectable 
IDO1 defect (NR-IDO1+) than in IDO1-defective patients (TCZ R and NR-IDO1−) (Figure 4G).
Therefore, because defective IDO1 patients were characterized by a prevalence of  the nonprotective 
IL6R rs2228145 genotype and, thus, higher IL-6R expression, these data confirm the importance of  a link 
between IL-6R signaling and IDO1 defect in T1D and further underline the distinctive immune features 
identified in the 3 subgroups of  pediatric patients with autoimmune diabetes (Table 4).
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IDO1-mediated, immunotherapeutic effects of  TCZ in diabetic NOD mice. In order to understand wheth-
er the TCZ effects in vitro on human PBMCs from pediatric patients with T1D could be of  therapeutic 
importance, we performed parallel experiments with NOD mice. In fact, in NOD mice, IDO1 expression 
and activity are almost negligible under inflammatory conditions (24, 25, 29), possibly due to an overpro-
duction of  IL-6, particularly evident in pancreata (26). A previous study reported that the systemic admin-
istration of  IL-6–neutralizing antibodies results in a marked suppression of  the diabetic disease in those 
animals (49). We have recently demonstrated that a proteasomal inhibitor approved for multiple myeloma 
therapy, besides protecting NOD mice from autoimmune diabetes in an IDO1-dependent fashion, signifi-
cantly upregulates IDO1 protein expression and activity in NOD splenocytes and PLN cells in vitro (27).
In order to corroborate our data suggesting an aberrant IL-6R signaling leading to an accelerated pro-
teasomal degradation of  IDO1 in a selected group of  T1D patients (i.e., TCZ R), we performed Western 
blot analysis of  IDO1 protein expression and Kyn measurements using PBMCs from T1D patients of  the 
TCZ R, NR IDO1+, and NR IDO1− phenotype, either untreated or treated in vitro with IFN-γ, a protea-
somal inhibitor (i.e., MG132), or a combination of  the 2 reagents. Representative blots and densitometric 
analyses of  15 such blots (Supplemental Figure 5, A and B) suggested that MG132, in combination with 
IFN-γ, significantly increases IDO1 protein expression and activity in TCZ R but not NR IDO1+ and NR 
IDO1− PBMCs.
Because of  the proven pathogenetic role of  IL-6 in NOD mice and the similar effects of  BTZ in mouse 
and human settings, we performed experiments with TCZ in NOD animals. Based on the ability of  TCZ 
to rectify IDO1 activity in PLN and spleen cells from NOD mice in vitro (Supplemental Figure 6), and 
because preliminary experiments indicated that the therapeutic efficacy of  TCZ is inversely related to glyce-
mia (data not shown), NOD animals with a glycemia of  200–250 mg/dl were administered TCZ or vehicle 
alone. At 3 months of  drug treatment, all control mice (i.e., on vehicle alone) were markedly hyperglycemic 
(Figure 5, A and B). In contrast, greater than 70% of  TCZ-treated animals had glycemia levels below 170 
mg/dl at about 1−3 weeks of  TCZ treatment. Glycemia remained in the range of  120–170 mg/dl for the 
entire duration of  the experiment. Histological analyses of  pancreata at 3 months of  treatment revealed the 
presence of  several islets without invasive insulitis or with minimal or no peri-insulitis in mice administered 
TCZ (Figure 5, C and D, and Supplemental Figure 6). In order to evaluate the role of  IDO1 in TCZ thera-
peutic effects, we treated diabetic NOD mice lacking IDO1 expression, recently generated in our laboratory 
(Methods and F. Fallarino, unpublished observations), with the same regimen of  TCZ used for WT NOD 
animals. The results indicated that TCZ’s efficacy in terms of  normalization of  glycemia, after a transient 
period of  3 weeks, was lost in the vast majority (>80%) of  NOD Ido1–/– mice (Figure 5, E and F). Similar-
ly, lack of  IDO1 expression also abrogated TCZ effects in terms of  histopathology (Figure 5, G and H). 
The apparently incomplete reversal of  TCZ effectiveness in Ido1−/− NOD animals may indicate that IL-6R 
blockade also acts, at least in part, via IDO1-independent mechanisms in autoimmune diabetes.
Thus, our data indicated that — similarly to IL-6 neutralization — IL-6R blockade is therapeutically 
effective in an experimental model of  mouse autoimmune diabetes, and in addition, TCZ effects do require 
IDO1 expression. Furthermore, our data suggest that the NOD strain may represent a predictive experi-
mental model for some (i.e., those connoted here as TCZ R and characterized by an excessive proteasomal 
degradation of  IDO1) but not all patients with T1D.
Discussion
Current treatment of  T1D is substitutive and — despite major constraints of  hypoglycemia and multiple 
insulin injections, as well as incomplete control of  cardiovascular complications over the long term — 
guarantees a good quality of  life in the majority of  patients (50). Although encouraging results have been 
obtained with anti-CD3 (51–53) and -CD20 (54) antibodies, no immunotherapy currently exists that can 
effectively halt the immune-mediated destruction of  β cells in human T1D (55). An important caveat of  past 
clinical trials might lie in a substantial disease heterogeneity of  T1D patients (56). A recent study indeed 
indicated that T1D is characterized by the existence of  distinct endotypes, reflecting different pathophysio-
logical states (57). Thus, a personalized immunotherapy may be required for effective T1D immunotherapy.
Prompted by our previous observations in NOD mice (24–27, 29, 58), we here investigated whether an 
IDO1 defect could also be demonstrated in the blood of  children with T1D and, if  so, which mechanism/s 
could be possibly involved and whether the defect could be corrected. Determinations of  Kyn in both sera 
and supernatants of  PBMCs stimulated with IFN-γ, the main IDO1 inducer, clearly indicated that the 
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majority of  patients with T1D is characterized by defective Trp catabolism, although sera but not in vitro 
measurements were found to have a linear relationship with age. Our data also indicated that defective 
IDO1 activity in PBMCs from children with T1D is mainly imputable to a deregulated IL-6 signaling — 
associated with a prevalence of  the AA rs2228145 IL6R genotype causing increased expression of  mem-
brane IL-6R (42) and risk for T1D (48) — that would favor IDO1 proteasomal degradation in inflammato-
ry environments, i.e., dominated by IFN-γ. Cell incubation with TCZ, an IL-6R blocker, restored normal 
levels of  IDO1 catalytic activity in response to IFN-γ in PBMCs from approximately one third — but not 
all — of  the examined T1D population. PBMCs from TCZ Rs showed peculiar characteristics upon stim-
ulation with IFN-γ — namely, they could be categorized as IDO1hiIL6RhiKynlo and carried the CT or CC 
allele at rs7820268 IDO1. In vitro treatment of  PBMCs from TCZ Rs with the IL-6 blocker also increased 
production of  TGF-β, an immunosuppressive cytokine that generally opposes IL-6 effects (59) and has 
been recognized as a positive modulator of  IDO1 expression and activity (45, 46, 60). TCZ NRs could be 
differentiated in 2 additional T1D subgroups, those upregulating and not upregulating IDO1 expression 
and activity. Although the occurrence of  T1D patients with physiological IDO1 expression may detract 
from the importance of  IDO1 as a restraint mechanism of  juvenile diabetes, our current data emphasized 
the fact that human T1D is heterogeneous in nature, and they suggest that personalized approaches may be 
mandatory for an effective immunotherapy of  all T1D patients. As a matter of  fact, PBMCs from IDO1hiIL-
6RloKynhi TCZ NRs, while upregulating IDO1 activity in response to IFN-γ, significantly downregulated 
Trp catabolism in the presence of  the drug, possibly indicating that cautions should be taken in treating 
uncharacterized T1D patients, at least in pediatric diabetology.
Although we cannot predict the exact individual response of PBMCs to a specific cytokine milieu in vivo, 
our data would point to 2 specific cytokines, IL-6 and TGF-β, playing a major role in affecting IDO1 expression 
in PBMCs from T1D patients. Thus, maneuvers capable of downregulating IL-6 signaling and/or upregulating 
TGF-β activity may be therapeutically effective in promoting IDO1-mediated tolerogenic mechanisms in T1D.
In conclusion, our study demonstrated that the majority of  T1D patients are characterized by a sub-
stantial defect in Trp catabolism detectable in whole PBMCs and that maneuvers aimed at restoring IDO1 
function would be therapeutically effective in at least a portion of  T1D patients. Because the IDO1 defect 
was found to be mainly associated with dysregulated IL-6 responsiveness, IDO1 and IL-6R may represent 
reliable biomarkers for stratified immunotherapeutic approaches in T1D patients.
Methods
Subject recruitment. Peripheral venous blood (3−5 ml) was obtained from T1D patients of  European descent 
and age-matched children (i.e., those without T1D or any autoimmune or allergic disease) attending the 
Day Service of  S. Maria della Misericordia Hospital (Perugia, Italy); the Juvenile Diabetes Center, Anna 
Meyer Children’s Hospital (Florence, Italy); and the Unit of  Endocrinology and Diabetes, ‘Bambino Gesù’ 
Children’s Hospital (Rome, Italy) during the years 2009−2017. A total of  165 patients with T1D and 87 
control subjects were recruited to this study (University of  Perugia Ethical Committee). Main subject 
demographic and disease characteristics are summarized in Table 1. Typically, blood from T1D patients 
and control subjects was drawn at the same time of  the day to avoid any potential confounding effects of  
diurnal rhythm and season, as well as experimental variability. To limit the effects of  diet on circulating 
Trp, serum samples were collected after an overnight fasting. Individuals included in our studies were free 
of  known infections at the time of  blood collection. Due to the small blood volume that can be obtained 
from pediatric subjects, all assays were not performed on each sample. Metabolic control was assessed 
by measurement of  HbA1c and glycemia at the time of  blood sampling. In the genetic discovery study, 
genomic DNA samples from the children recruited within the functional study, and from additional 100 
children with T1D (Hôpital Necker-Enfants Malades) and 361 controls, were screened for IDO1 SNPs. A 
replication set of  206 adults with T1D and matched controls (CICS-UBI) was used to validate the results 
from the discovery set.
Cell purification. PBMCs were isolated on a Ficoll-Hypaque gradient and left untreated or exposed for 
48 hours at 37°C to IFN-γ (100–1,000 U/ml; Novus Biologicals LLC) in the presence or absence of  10 μg/
ml TCZ (Chugai Pharmaceutical Co.) or 10 μM MG132 (MilliporeSigma) in complete medium (RPMI 
with 10% FCS, 10 mM HEPES, and 50 μM 2-ME). All experiments were performed with 5 × 105/well 
PBMCs in 24-well plates. Sera were obtained by blood centrifugation at 450 g for 5 minutes and frozen at 
−80°C in criovials until analyses.
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Kyn assay, real-time PCR, immunoblot analysis, and cytokine determination. IDO1 activity was measured 
in terms of  the ability to metabolize Trp to Kyn, whose concentration was measured by HPLC in super-
natants of  PBMCs at 48 hours of  culture after the addition of  100 μM Trp for the final 8 hours. Kyn and 
Trp were also measured in sera by HPLC as described (61). Kyn/Trp ratios were calculated dividing 
Kyn (μmol per liter) by Trp concentrations (mmol per liter) concentrations (62). Real-time PCR analysis 
was done as described (45, 60) with primers specific for human IDO1, IL6, IL6R, and SOCS3. Data were 
presented as the ratio of  gene expression to ACTB (coding for human β-actin) expression determined 
by the relative quantification method (ΔCT). IDO1 expression was investigated by immunoblot with 
an affinity purified, mouse mAb (clone 4.16H1) highly specific for human IDO1 (63) in lysates from 
PBMCs cultured for 48 hours with complete medium either alone or in the presence of  IFN-γ and/
or TCZ. Rabbit polyclonal Abs with specificity for human SOCS3 (catalog 2923) and IL-6R (cata-
log 128008) were from Cell Signaling Technology and Abcam, respectively. Anti−human β-tubulin Ab 
(clone AA2, MilliporeSigma) was used as a normalizer. Relative protein expression was quantified by 
using an ImageQuant TL LAS4000 mini densitometer and the Analysis Toolbox software (GE Health-
care). Densitometric analysis of  the specific signals was performed within a linear range of  exposure 
of  the blots, selecting in each experiment the 2 lowest exposure times useful to detect the signals, as 
described (64). Human IL-6 and TGF-β1 concentrations were determined in PBMC supernatants by 
using specific ELISA kits (eBioscience Inc. and Promega Corporation, respectively).
Genetic screening. Genomic DNA from whole blood samples was isolated using the QIAamp DNA 
Blood Mini kit (QIAGEN) following the manufacturer’s instructions and stored at −20°C. SNPs in IDO1 
were selected either from the literature (rs9657182) (22) or based on their ability to tag surrounding vari-
ants in the HapMap-CEU population of  the International HapMap project, NCBI build B36 assembly 
HapMap phase III (http://www.hapmap.org). The Haploview version 4.2 software was used to select hap-
lotype-based tagSNPs by assessing LD blocks with a pairwise correlation coefficient r2 of  at least 0.80 and 
minor allele frequency of  >0.5 in the HapMap-CEU population using the confidence intervals method (65) 
and the LD-plot function of  this software. Genotype frequencies were used to derive haplotype configura-
tions and calculate Hardy-Weinberg equilibrium using the accelerated expectation-maximization algorithm 
similar to the partition/ligation method (66). Evaluated SNPs and haplotypes are indicated in Figure 2A 
and Table 2. For the IL6R gene, the functional SNP rs2228145 was selected for analysis (67). Genotyping 
was performed using the KASPar chemistry (LGC Genomics) according to the manufacturer’s instruc-
tions in an Applied Biosystems 7500HT Fast qPCR system (Invitrogen). Each genotyping set comprised 
randomly selected replicates of  sequenced samples and negative controls. Concordant genotyping was 
obtained for ˃99% of  the assays. Laboratory personnel were blind to the sample status.
Drug administration, histopathology, cell purification, and cytokine determinations in mice. NOD/MrkTac female 
mice, 12 weeks old, were purchased from Taconic. Ido1−/− NOD mice were derived by means of  backcross-
ing of  Ido1−/− C57/BL6 animals into the NOD/MrkTac strain. After 10 backcrossings, analysis of  DNA 
microsatellite markers demonstrated the complete transfer of  KO Ido1 into NOD mice (F. Fallarino, unpub-
lished observations). For TCZ treatment, NOD mice, either proficient or deficient for Ido1 expression, were 
recruited when their glycemia was in the range of  200–250 mg/dl. TCZ or saline was administered i.p. at the 
dose of  5 mg/kg every other day for 3 weeks and once a week until the end of  the experiment. Animals were 
sacrificed for ex vivo analyses at different times from the initiation of  drug treatment. For histopathology, 3–4 
μm of paraffin-embedded sections of  pancreata (5 per organ) were stained with H&E and analyzed by light 
microscopy. Insulitis scoring was according to standard criteria as described (26, 29). Pancreatic leukocytes 
and splenocytes were purified and their cytokine production measured as described (26, 27).
Statistics. All analyses were performed using Prism version 6.0 (GraphPad Software). Data usually 
met normality and were analyzed by 2-tailed unpaired Student’s t test or 2-way ANOVA followed by 
post hoc Bonferroni’s test, when 3 or more samples were under comparison, respectively. Alternatively, 
the nonparametric Mann-Whitney test or Kruskal-Wallis with post hoc Dunn’s test was used. A P value 
less than 0.05 was considered significant. Overall results, obtained by at least 3 replicates per experi-
mental parameter, were shown as mean (± SEM). Association between 2 variables was analyzed by 
the least square regression analysis. Multiple regression analysis was used to test whether clinical char-
acteristics significantly predicted Trp catabolism in sera and supernatants. IDO1 allele and genotype 
distributions were compared using Fisher’s exact test. Significance tests for the haplotype analyses were 
calculated based on approximate χ2 distribution.
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In mice, data of  diabetes incidence were analyzed by Kaplan-Meier. Survival curves were compared by 
log-rank test. Ex vivo determinations, shown as means ± SD, were from at least 3 independent experiments 
and compared by 2-tailed unpaired Student’s t test. Mice were considered nondiabetic when glycemia mea-
surement gave values <200 mg/ml on at least 3 consecutive measurements (3 per week).
Study approval. All parents provided informed written consent for the collection of  samples and sub-
sequent analysis. Ethical approvals were as follows: University of  Perugia Ethical Committee, 19.1.2009, 
2013-50, and 2016-05; Hôpital Necker-Enfants Malades, ID-RCB 2008-A01538-47; and CICS-UBI, 
CE-FCS-2011-003 and 2013-017. Each child in scholar age was informed orally about the study by a nurse 
immediately before blood drawing during routine analyses. In vivo studies were in compliance with nation-
al (Italian Approved Animal Welfare Assurance A-3143-01) and Perugia University Animal Care and Use 
Committee guidelines.
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